$OCGN BBV152 (COVAXIN) COVID-19 (within U.S.) Phase 2 Emergency Use Authorization (EUA) submitted to FDA for children ages 2-18 years, announced November 5, 2021. Phase 2 data reported that 75% had an antibody response 6 months post second dose and after receiving the booster, participants also saw an increase in antibody titers higher than those achieved after the two-dose primary series, noted January 8, 2022. Phase 2 data reported that 100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant, noted January 12, 2022.